Cantor Fitzgerald Predicts VNDA FY2025 Earnings

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings estimates for Vanda Pharmaceuticals in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan forecasts that the biopharmaceutical company will post earnings of $1.30 per share for the year. The consensus estimate for Vanda Pharmaceuticals’ current full-year earnings is ($0.32) per share.

Several other research analysts have also recently issued reports on VNDA. StockNews.com assumed coverage on Vanda Pharmaceuticals in a research report on Monday. They issued a “hold” rating on the stock. HC Wainwright restated a “buy” rating and set a $18.00 target price on shares of Vanda Pharmaceuticals in a research report on Tuesday.

Vanda Pharmaceuticals Stock Performance

Shares of VNDA stock opened at $4.35 on Thursday. Vanda Pharmaceuticals has a 12-month low of $3.46 and a 12-month high of $6.75. The firm’s 50 day moving average is $4.79 and its 200 day moving average is $5.02.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. ORG Wealth Partners LLC purchased a new stake in shares of Vanda Pharmaceuticals in the third quarter worth about $40,000. China Universal Asset Management Co. Ltd. increased its stake in Vanda Pharmaceuticals by 64.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 4,374 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Vanda Pharmaceuticals during the 2nd quarter worth approximately $75,000. Intech Investment Management LLC bought a new position in shares of Vanda Pharmaceuticals during the 3rd quarter valued at approximately $84,000. Finally, SG Americas Securities LLC increased its position in Vanda Pharmaceuticals by 88.5% in the third quarter. SG Americas Securities LLC now owns 20,402 shares of the biopharmaceutical company’s stock worth $96,000 after purchasing an additional 9,580 shares during the last quarter. Institutional investors own 88.14% of the company’s stock.

Insider Activity at Vanda Pharmaceuticals

In other Vanda Pharmaceuticals news, Director Stephen Ray Mitchell sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $5.17, for a total value of $25,850.00. Following the completion of the transaction, the director now directly owns 44,857 shares in the company, valued at $231,910.69. This represents a 10.03 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 8.90% of the stock is owned by corporate insiders.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.